Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on cancer treatments, has announced its participation in two major investor conferences in December 2024. The company's senior leadership will be available for one-on-one meetings with investors at both events.
The first appearance will be at the 36th Annual Piper Healthcare Conference in New York on December 3, featuring a fireside chat from 10:00-10:25 AM ET. The second event is the 7th Annual Evercore HealthCONx in Coral Gables, FL on December 5, with a fireside chat scheduled for 10:50-11:10 AM ET. Both events will be webcasted and available for replay for 90 days through the company's investor website.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda radioterapica focalizzata sui trattamenti per il cancro, ha annunciato la sua partecipazione a due importanti conferenze per investitori a dicembre 2024. I dirigenti senior dell'azienda saranno disponibili per incontri individuali con gli investitori in entrambi gli eventi.
La prima apparizione sarà alla 36a Conferenza Sanitaria Annuale Piper a New York il 3 dicembre, con una chiacchierata informale dalle 10:00 alle 10:25 AM ET. Il secondo evento è la 7a Conferenza Annuale Evercore HealthCONx a Coral Gables, FL, il 5 dicembre, con una chiacchierata informale programmata dalle 10:50 alle 11:10 AM ET. Entrambi gli eventi saranno trasmessi in diretta e disponibili per la visione on-demand per 90 giorni attraverso il sito web dedicato agli investitori dell'azienda.
Perspective Therapeutics (NYSE AMERICAN: CATX), una empresa de radiofármacos centrada en tratamientos para el cáncer, ha anunciado su participación en dos importantes conferencias para inversionistas en diciembre de 2024. El liderazgo senior de la empresa estará disponible para reuniones uno a uno con inversionistas en ambos eventos.
La primera aparición será en la 36ª Conferencia Anual de Salud de Piper en Nueva York el 3 de diciembre, con una charla informal programada de 10:00 a 10:25 AM ET. El segundo evento es la 7ª Conferencia Anual Evercore HealthCONx en Coral Gables, FL, el 5 de diciembre, con una charla informal programada de 10:50 a 11:10 AM ET. Ambos eventos se transmitirán por web y estarán disponibles para repetición durante 90 días a través del sitio web para inversionistas de la empresa.
Perspective Therapeutics (NYSE AMERICAN: CATX), 암 치료에 중점을 둔 방사선 제약 회사가, 2024년 12월에 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 고위 경영진은 두 행사 모두에서 투자자와의 일대일 미팅을 위해 대기할 예정입니다.
첫 번째 행사는 12월 3일 뉴욕에서 열리는 제36회 파이퍼 헬스케어 회의이며, 오전 10시부터 10시 25분까지 화기애애한 대담이 진행될 예정입니다. 두 번째 행사는 12월 5일 플로리다주 코랄 게이블스에서 열리는 제7회 에버코어 헬스컨 엑스포이며, 오전 10시 50분부터 11시 10분까지 화기애애한 대담이 예정되어 있습니다. 두 행사는 웹캐스트로 송출되며, 회사의 투자자 웹사이트를 통해 90일 동안 재생 가능합니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une entreprise de radio-pharmaceutiques axée sur les traitements contre le cancer, a annoncé sa participation à deux grandes conférences pour investisseurs en décembre 2024. Les dirigeants de l'entreprise seront disponibles pour des réunions individuelles avec des investisseurs lors des deux événements.
La première apparition aura lieu lors de la 36ème Conférence Annuelle Piper Healthcare à New York le 3 décembre, avec une discussion informelle prévue de 10h00 à 10h25 (ET). Le deuxième événement est la 7ème Conférence Annuelle Evercore HealthCONx à Coral Gables, FL, le 5 décembre, avec une discussion informelle prévue de 10h50 à 11h10 (ET). Les deux événements seront diffusés en direct et disponibles en replay pendant 90 jours via le site internet des investisseurs de l'entreprise.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein auf Krebsbehandlungen spezialisiertes Radiopharmaunternehmen, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember 2024 angekündigt. Die leitenden Führungskräfte des Unternehmens werden bei beiden Veranstaltungen für Einzelgespräche mit Investoren zur Verfügung stehen.
Der erste Auftritt findet am 3. Dezember auf der 36. Jahreskonferenz von Piper Healthcare in New York statt, mit einem offenen Gespräch von 10:00 bis 10:25 Uhr ET. Die zweite Veranstaltung ist die 7. Jahreskonferenz von Evercore HealthCONx in Coral Gables, FL, am 5. Dezember, mit einem offenen Gespräch, das für 10:50 bis 11:10 Uhr ET angesetzt ist. Beide Veranstaltungen werden im Internet übertragen und sind für 90 Tage über die Investorenseite des Unternehmens auf Abruf verfügbar.
- None.
- None.
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.
36th Annual Piper Healthcare Conference
Date: December 3, 2024
Location: New York, NY
Format: Fireside Chat
Time: 10:00-10:25 AM ET
7th Annual Evercore HealthCONx
Date: December 5, 2024
Location: Coral Gables, FL
Format: Fireside Chat
Time: 10:50-11:10 AM ET
Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
FAQ
When is Perspective Therapeutics (CATX) presenting at the Piper Healthcare Conference?
Where can I watch Perspective Therapeutics (CATX) investor conference webcasts?
What type of meetings will Perspective Therapeutics (CATX) offer at the December 2024 conferences?
When is Perspective Therapeutics (CATX) presenting at the Evercore HealthCONx conference?
